DK3628319T3 - Behandling af hepatisk encefalopati ved anvendelse af rifaximin - Google Patents

Behandling af hepatisk encefalopati ved anvendelse af rifaximin Download PDF

Info

Publication number
DK3628319T3
DK3628319T3 DK19207534.9T DK19207534T DK3628319T3 DK 3628319 T3 DK3628319 T3 DK 3628319T3 DK 19207534 T DK19207534 T DK 19207534T DK 3628319 T3 DK3628319 T3 DK 3628319T3
Authority
DK
Denmark
Prior art keywords
rifaximin
treatment
hepatic encephalopathy
encephalopathy
hepatic
Prior art date
Application number
DK19207534.9T
Other languages
Danish (da)
English (en)
Inventor
William Forbes
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42073897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3628319(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Application granted granted Critical
Publication of DK3628319T3 publication Critical patent/DK3628319T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Emergency Medicine (AREA)
DK19207534.9T 2008-10-02 2009-10-02 Behandling af hepatisk encefalopati ved anvendelse af rifaximin DK3628319T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10234908P 2008-10-02 2008-10-02
EP09818544.0A EP2350096B1 (en) 2008-10-02 2009-10-02 Methods of treating hepatic encephalopathy

Publications (1)

Publication Number Publication Date
DK3628319T3 true DK3628319T3 (da) 2024-03-04

Family

ID=42073897

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09818544.0T DK2350096T3 (da) 2008-10-02 2009-10-02 Fremgangsmåder til behandling af hepatisk encephalopati
DK19207534.9T DK3628319T3 (da) 2008-10-02 2009-10-02 Behandling af hepatisk encefalopati ved anvendelse af rifaximin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK09818544.0T DK2350096T3 (da) 2008-10-02 2009-10-02 Fremgangsmåder til behandling af hepatisk encephalopati

Country Status (21)

Country Link
US (12) US20100204173A1 (enExample)
EP (4) EP4342465A3 (enExample)
JP (2) JP6037615B2 (enExample)
CN (1) CN102245615A (enExample)
AU (1) AU2009298389C1 (enExample)
BR (1) BRPI0920465A2 (enExample)
CA (1) CA2739436C (enExample)
CY (1) CY1122806T1 (enExample)
DK (2) DK2350096T3 (enExample)
ES (2) ES2972135T3 (enExample)
FI (1) FI3628319T3 (enExample)
HR (2) HRP20240317T1 (enExample)
HU (2) HUE048293T2 (enExample)
IL (1) IL212055A0 (enExample)
LT (2) LT2350096T (enExample)
MX (2) MX364102B (enExample)
PL (2) PL2350096T3 (enExample)
PT (2) PT3628319T (enExample)
SI (2) SI2350096T1 (enExample)
SM (2) SMT202400116T1 (enExample)
WO (1) WO2010040020A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
ES2522895T3 (es) 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
HRP20240317T1 (hr) 2008-10-02 2024-06-07 Salix Pharmaceuticals, Ltd. Liječenje hepatičke encefalopatije uporabom rifaksimina
EP3964066A1 (en) * 2009-06-02 2022-03-09 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
WO2010148040A1 (en) * 2009-06-15 2010-12-23 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
PT2493471T (pt) 2009-10-26 2020-01-09 Borody Thomas J Nova terapia de combinação entérica
BR112013002667B1 (pt) 2010-08-04 2020-02-04 Thomas Julius Borody composições para transplante da flora intestinal e métodos para fazê-las e usá-las e dispositivos para administrá-las
WO2012076832A1 (en) * 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
BR112013022927A2 (pt) 2011-03-09 2016-12-06 Univ Minnesota composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
AU2012332211B2 (en) 2011-11-02 2016-11-24 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (IBS) and infections
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
ITBO20120368A1 (it) * 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
JP2015528507A (ja) * 2012-09-13 2015-09-28 サリックス ファーマスーティカルズ，インコーポレーテッド 肝性脳症を患う対象の長期生存を改善し、再入院率を低減する方法
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
WO2014107657A2 (en) * 2013-01-04 2014-07-10 Kohn Kenneth I Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
AU2014262125B2 (en) * 2013-04-30 2020-02-13 Thomas Julius Borody Compositions and methods for treating microbiota-related psychotropic conditions and diseases
CN103340856A (zh) * 2013-07-09 2013-10-09 荣港生技医药科技（北京）有限公司 一种利福昔明药物组合物及其制备方法
DK3099306T3 (en) 2014-01-29 2019-03-18 Umecrine Cognition Ab STEROID RELATIONSHIP TO USE IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY
EP2927235B1 (en) 2014-03-31 2017-02-08 Euticals S.P.A. Polymorphic mixture of rifaximin and its use for the preparation of solid formulations
PT3143027T (pt) 2014-05-12 2019-09-20 Alfasigma Spa Nova forma de cristal solvatado de rifaximina, produção, composições e utilização dos mesmos
AU2015284782B2 (en) * 2014-06-30 2020-05-07 Salix Pharmaceuticals, Inc. Methods for retreating Irritable Bowel Syndrome (IBS)
TWI748936B (zh) 2015-01-12 2021-12-11 瑞典商優鎂奎認知Ａｂ公司 新穎化合物
WO2016183577A1 (en) 2015-05-14 2016-11-17 Crestovo Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
BR112017024777A2 (pt) 2015-05-22 2018-08-07 Univ Arizona State uso de uma composiçao farmacêutica e de um antibiótico não absorvível para tratamento de transtorno do espectro autista referência cruzada a pedidos relacionados?
EP3399973A4 (en) * 2016-01-08 2019-09-04 Colonaryconcepts LLC ON FOOD BASED RELEASE OF A THERAPEUTIC FOR THE TREATMENT OF HEPATIC ENZEPHALOPATHY
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
EP4137132A1 (en) 2016-09-30 2023-02-22 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
CN106822119A (zh) * 2017-02-28 2017-06-13 丹诺医药(苏州）有限公司 一种利福霉素‑硝基咪唑偶联分子的新用途
CN106822125A (zh) * 2017-02-28 2017-06-13 丹诺医药(苏州）有限公司 一种利福霉素‑喹嗪酮双靶标分子的新用途
EP3606541A1 (en) 2017-04-05 2020-02-12 Crestovo Holdings LLC Compositions and methods for treating parkinson's disease (pd) and related disorders
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
AU2018272048B2 (en) 2017-05-26 2024-04-04 Finch Therapeutics Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
CN111328284A (zh) 2017-08-07 2020-06-23 芬奇治疗公司 用于维持和恢复健康的肠道屏障的组合物和方法
KR102747348B1 (ko) 2017-11-10 2024-12-31 코스모 테크놀러지스 리미티드 경구 리파마이신 sv 조성물
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
EP3836801A4 (en) 2018-08-16 2022-05-18 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
AU2019351017A1 (en) 2018-09-27 2021-04-29 Finch Therapeutics Holdings Llc. Compositions and methods for treating epilepsy and related disorders
EP3897681A4 (en) 2018-12-20 2022-10-26 Société des Produits Nestlé S.A. DOSING SCHEDULE APPLICABLE FOR ORAL IMMUNOTHERAPY AGAINST PEANUT FOR MISSED DOSES
CN113966229A (zh) 2019-05-10 2022-01-21 爱沐疗法公司 用于改善花生过敏患者的生活质量的方法
WO2020245214A1 (en) * 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
CN115944654A (zh) 2019-07-19 2023-04-11 芬奇治疗控股有限责任公司 用于治疗胃肠道病症的方法及产品
US20230111568A1 (en) * 2020-03-24 2023-04-13 Bausch Health Ireland Limited Solid dispersions of rifaximin for the treatment of overt hepatic encephalopathy
US20250345400A1 (en) * 2022-05-18 2025-11-13 Virginia Commonwealth University Methods for treatment of cognitive impairment in cirrhosis patients
WO2025064599A1 (en) * 2023-09-19 2025-03-27 The United States Government As Represented By The Department Of Veterans Affairs Rifamycin composition for treating sarcopenia
WO2025157240A1 (zh) * 2024-01-26 2025-07-31 丹诺医药（苏州）股份有限公司 化合物用于制备治疗细菌代谢相关疾病的药物的用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132910A (en) 1962-03-26 1964-05-12 Eastman Kodak Co Cabinetry structure
US3132908A (en) 1962-04-02 1964-05-12 Carrier Corp Thrust bearing construction
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
US4343785A (en) 1981-08-10 1982-08-10 Basf Wyandotte Corporation Gel dentifrice compositions
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
AU5171293A (en) 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
IT1264494B1 (it) 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6562629B1 (en) * 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
ES2114502B1 (es) 1996-07-29 1999-07-01 Univ Santiago Compostela Aplicacion de nanoparticulas a base de polimeros hidrofilicos como formas farmaceuticas.
WO1998010649A1 (en) 1996-09-13 1998-03-19 University Technology Corporation Biocompatible cationic detergents and uses therefor
IT1290679B1 (it) 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
US20020028764A1 (en) 2000-09-04 2002-03-07 Aarhus Amt. Treatment of acute and chronic liver disease
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
US20040229948A1 (en) * 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US20040077533A1 (en) * 2002-05-23 2004-04-22 Sayada Chalom B. Methods and compositions for treating bacterial infections and diseases associated therewith
US20090149453A1 (en) * 2002-05-23 2009-06-11 Activbiotics Pharma Llc Methods and compositions for treating bacterial infections and diseases associated therewith
AU2003268330A1 (en) * 2002-08-29 2004-03-19 Activbiotics, Inc. Methods and reagents for treating infections of clostridium difficile and diseases associated therewith
TW200418485A (en) * 2002-09-23 2004-10-01 Activbiotics Inc Rifalazil compositions and therapeutic regimens
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7256202B2 (en) 2003-12-31 2007-08-14 Halow George M Composition and method for treatment of hepatic encephalopathy
DE602005019319D1 (de) 2004-11-26 2010-03-25 Ucl Business Plc Zusammensetzungen mit ornithin und phenylacetat oder phenylbutyrat zur behandlung von hepatischer enzephalopathie
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
ES2522895T3 (es) 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
WO2006102536A2 (en) 2005-03-23 2006-09-28 University Of Southern California Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
DK1996710T3 (da) 2006-03-09 2019-10-07 Salix Pharmaceuticals Inc Rifaximin-præparat mod rektal dysfunktion
WO2008011595A2 (en) 2006-07-21 2008-01-24 Lab International Srl Hydrophobic abuse deterrent delivery system
CN101534840A (zh) 2006-08-02 2009-09-16 萨利克斯药品公司 治疗放射性肠炎的方法
MX2009001342A (es) 2006-08-02 2009-08-31 Salix Pharmaceuticals Inc Composiciones y metodos para el tratamiento de proctosigmoiditis por radiacion.
EP2069363B1 (en) 2006-09-22 2013-03-20 Cipla Ltd. Rifaximin in an amorphous form
US20100136125A1 (en) 2006-12-28 2010-06-03 Jacobus Pharmaceutical Company, Inc. Method of treating inflammatory bowel disease
SI2011486T1 (sl) 2007-07-06 2012-10-30 Lupin Ltd Farmacevtski sestavki rifaksimina
JP5755878B2 (ja) * 2007-07-06 2015-07-29 ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミンの薬剤組成物
EA021176B1 (ru) 2008-02-25 2015-04-30 Сэликс Фармасьютиклз, Лтд. Полиморфная форма рифаксимина и её применение
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
KR20100122937A (ko) 2008-02-26 2010-11-23 샐릭스 파마슈티컬스 리미티드 장 질환의 치료 방법
US20100317681A1 (en) 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
HRP20240317T1 (hr) * 2008-10-02 2024-06-07 Salix Pharmaceuticals, Ltd. Liječenje hepatičke encefalopatije uporabom rifaksimina
US20110035232A1 (en) * 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
EP3964066A1 (en) * 2009-06-02 2022-03-09 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
DE102009052972A1 (de) 2009-11-12 2011-09-15 Lts Lohmann Therapie-Systeme Ag Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm
EP2340812A1 (en) 2009-12-18 2011-07-06 Ferring International Center S.A. Granules for pharmaceutical preparations, methods and apparatus for their production
LT2608792T (lt) 2010-08-26 2018-01-10 Boehringer Ingelheim International Gmbh Egfr inhibitoriaus vartojimo būdai
KR20130027255A (ko) * 2011-09-07 2013-03-15 삼성전자주식회사 키 조립체 및 이를 구비한 회전식 입력 장치
CN103945849B (zh) 2011-11-30 2017-04-26 阿斯利康(瑞典)有限公司 癌症的联合治疗
US10234908B2 (en) 2014-04-29 2019-03-19 Hewlett-Packard Develoment Company, L.P. Hinge assembly for a computing device
US20160191956A1 (en) * 2014-12-15 2016-06-30 Cable Television Laboratories, Inc. Software defined networking in a cable tv system
AU2016272881C1 (en) 2015-06-04 2019-10-03 Pfizer Inc. Solid dosage forms of palbociclib

Also Published As

Publication number Publication date
US10335397B2 (en) 2019-07-02
US20240066010A1 (en) 2024-02-29
CA2739436C (en) 2019-08-27
SMT202000124T1 (it) 2020-05-08
US20170281606A1 (en) 2017-10-05
US9949958B2 (en) 2018-04-24
US20150157612A1 (en) 2015-06-11
PL3628319T3 (pl) 2024-04-29
MX2011003548A (es) 2011-06-21
EP4342465A2 (en) 2024-03-27
US11633384B2 (en) 2023-04-25
US20100204173A1 (en) 2010-08-12
PL2350096T3 (pl) 2020-06-29
SI2350096T1 (sl) 2020-08-31
JP6037615B2 (ja) 2016-12-07
LT3628319T (lt) 2024-03-25
HRP20200284T1 (hr) 2020-07-10
US20210275507A1 (en) 2021-09-09
CN102245615A (zh) 2011-11-16
PT3628319T (pt) 2024-03-22
CY1122806T1 (el) 2021-05-05
ES2972135T3 (es) 2024-06-11
AU2009298389C1 (en) 2016-04-28
US9629829B2 (en) 2017-04-25
US20180303804A1 (en) 2018-10-25
JP2012504649A (ja) 2012-02-23
US20200108051A1 (en) 2020-04-09
FI3628319T3 (fi) 2024-03-12
HUE048293T2 (hu) 2020-07-28
WO2010040020A1 (en) 2010-04-08
SMT202400116T1 (it) 2024-05-14
US20200368213A1 (en) 2020-11-26
EP2350096A1 (en) 2011-08-03
ES2770308T3 (es) 2020-07-01
DK2350096T3 (da) 2020-03-02
US10709694B2 (en) 2020-07-14
EP4591862A3 (en) 2025-10-15
US20230330071A1 (en) 2023-10-19
BRPI0920465A2 (pt) 2018-03-20
HRP20240317T1 (hr) 2024-06-07
HUE065491T2 (hu) 2024-05-28
AU2009298389B2 (en) 2015-06-11
US20130171090A1 (en) 2013-07-04
EP4342465A3 (en) 2024-06-12
PT2350096T (pt) 2020-03-05
LT2350096T (lt) 2020-03-10
SI3628319T1 (sl) 2024-04-30
EP4591862A2 (en) 2025-07-30
IL212055A0 (en) 2011-06-30
US8969398B2 (en) 2015-03-03
MX364102B (es) 2019-04-12
US20110243879A1 (en) 2011-10-06
US20240299368A1 (en) 2024-09-12
EP3628319B1 (en) 2024-02-14
AU2009298389A1 (en) 2010-04-08
EP2350096B1 (en) 2019-12-11
JP2015166381A (ja) 2015-09-24
CA2739436A1 (en) 2010-04-08
EP3628319A1 (en) 2020-04-01
EP2350096A4 (en) 2012-03-28

Similar Documents

Publication Publication Date Title
DK3628319T3 (da) Behandling af hepatisk encefalopati ved anvendelse af rifaximin
DK2350116T3 (da) Behandling af biofilm
DK2340031T3 (da) Gdf-fanger til anvendelse ved behandling af anæmi
DK2498771T3 (da) Anvendelse af bethanechol til behandling af xerostomi
DK2271642T3 (da) Pyridylinhibitorer af hedgehog signalering
DK2982696T3 (da) Behandling af akut lymfoblastær leukæmi
DK3289876T3 (da) Forbindelser til behandling af cancer
DK2111555T3 (da) Diagnosticering af præeklampsi
DK2358714T3 (da) Alkylcyclohexylethere af dihydrotetraazabenzoazulener
DK2373927T3 (da) Behandling af forbrændingsgas fra affaldsbehandling
DK2133330T3 (da) Atropisomer af pyrrolderivat
DK2382232T3 (da) Fremgangsmåde til fremstilling af bivalirudin
BRPI0820677A2 (pt) Misturas de compostos pesticidas
BRPI0908185A2 (pt) mecanismo de bloqueio
DK2421819T3 (da) Fremgangsmåde til iodering af aromatiske forbindelser
BRPI0911636A2 (pt) mecanismo de travamento
DK2435583T3 (da) miR-31 VED BEHANDLING AF DUCHENNES MUSKELDYSTROFI
DK2265415T4 (da) Fremgangsmåde til permanent samling af emner
DK2501381T3 (da) Behandling af atrieflimmer
DK2181065T3 (da) Partialoxidation af carbonhydrider
CU23884B1 (es) Derivados de dibenzotiazepina
DK2285416T3 (da) Konjugat til behandlingen af mesotheliom
DK2190451T3 (da) Behandling af atherosklerose
BRPI0821567A2 (pt) Misturas de compostos pesticidas
BRPI0820650A2 (pt) Misturas de compostos pesticidas